The Emergence of Multiple Sclerosis as a “Treatable” Condition; An Historical Perspective

  • W. Ian McDonald


Implicit in the statement that a disease is treatable is the idea that its course can be favourably modified by some kind of intervention. Until recently multiple sclerosis (MS) quite certainly has not been in this category. There is a widespread conviction that it now is, but such convictions have been held before and have proved unfounded. How can we be sure that our present confidence is justified? In this short review I shall trace the evolution of our attempts to treat MS, emphasizing strategies designed to arrest its progress. The development of the complementary and no less important approaches to relieving symptoms lies beyond my present scope.


Multiple Sclerosis Optic Neuritis Experimental Allergic Encephalomyelitis Total Lymphoid Irradiation Multiple Sclerosis Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams DK, Blacklock JWS, Dunlop EM et al. (1924) An investigation into the pathogenesis of disseminated sderosis. Q J Med 17:129–150Google Scholar
  2. Aimard G, Girard PF, Raveaou J (1966) Sclérose en plaques et processus d’autoimmunisation: traitement par les antimitotiques. Lyon Méd 215:345–353Google Scholar
  3. Association for Research in Nervous and Mental Diseases (1922) Multiple Sclerosis, vol 2, Hoeber, New YorkGoogle Scholar
  4. Baker RWR, Thompson RHS, Zilkha K (1963) Fatty acid composition of brain lecithins in multiple sclerosis. Lancet i:26–27Google Scholar
  5. Bates D, Cartlidge NEF, French JM et al. (1989) A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 52:18–22PubMedCrossRefGoogle Scholar
  6. Beck RW (1995) The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 113:136PubMedGoogle Scholar
  7. Beck RW, Cleary PA (1993) Optic neuritis treatment trial: one year follow-up results. Arch Ophthalmol 111:773–775PubMedGoogle Scholar
  8. Beck RW, Cleary PA, Anderson MM et al. (1992) A randomised, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581–588PubMedCrossRefGoogle Scholar
  9. Beck RW, Cleary RA, Trobe JD et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764–1769PubMedCrossRefGoogle Scholar
  10. Brickner RM (1935–1936) A critique of therapy in multiple sclerosis. Bull Neurol Inst NY 4:665–698 British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet ii:179–183Google Scholar
  11. Buzzard EF (1911) The treatment of disseminated sclerosis: A suggestion. Lancet i:98Google Scholar
  12. Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclosphosphamide and plasma exchange in progressive multiple sclerosis. Lancet i:441–446Google Scholar
  13. Carmichael EA (1931) The aetiology of disseminate sclerosis: some criticisms of recent work especially with regard to the ‘spherula insularis’. Proc R Soc Med 34:591–599Google Scholar
  14. Carswell R (1838) Pathological anatomy. Illustrations of the elementary forms of disease. Longman, Orme, Brown, Green and Longman, LondonGoogle Scholar
  15. Charcot JM (1877) Lectures on diseases of the nervous system (trans. Sigerson G). The New Sydenham Society, London 158Google Scholar
  16. Charcot M (1868) Histologie de le sclérose en plaques. Gazette des Hôpitaux, Paris 141:554–555, 557–558Google Scholar
  17. Chevassut K (1930) Aetiology of disseminated sclerosis. Lancet i:552–560Google Scholar
  18. Compston A (1988) The 150th anniversary of the first depiction of the lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 51:1249–1252CrossRefGoogle Scholar
  19. Cook SD, Devereux C, Troiano R et al. (1987) Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neural 22:634–638CrossRefGoogle Scholar
  20. Cruveilhier J (1835–1842) Anatomie pathologique du corps humain; descriptions avec figures lithographiées et coloriées; des diverses alterations morbides dont le corps humain est susceptible. Baillière, ParisGoogle Scholar
  21. Cushny AR (1910) A textbook of pharmacology and therapeutics, 5th edn. Lea and Febiger, Philadelphia, pp 623, 691Google Scholar
  22. Denny-Brown D (1952) Multiple sclerosis: the clinical problem. Am J Med 12:501–509PubMedCrossRefGoogle Scholar
  23. Firth D (1948) The case of Augustus D’Esté. Cambridge University Press, Cambridge, pp 25–27 Grosz K (1924) Malaria-behandlung der multiplen Sderose. Jahrkuch Psychiatr Neural 43:198–214Google Scholar
  24. The Emergence of Multiple Sclerosis as a “Treatable” Condition: An Historical Perspective 359Google Scholar
  25. Gye NE (1921) The experimental study of disseminated sclerosis. Brain 44:213–222CrossRefGoogle Scholar
  26. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661Google Scholar
  27. Jacobs L, Cookfaire D, Ludick R et al. (1994) Results of a Phase III trial of intramuscular recombinant beta-interferon as treatment for multiple sclerosis. Ann Neurol 36:259CrossRefGoogle Scholar
  28. Johnson KP (1994) Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. Ann Neurol 36:5115–5117Google Scholar
  29. Johnson RT (1982) Viral infections of the nervous system. Raven Press, New YorkGoogle Scholar
  30. Kappos L, Patzold U, Dommasch D et al. (1988) Cydosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol 23:56–63PubMedCrossRefGoogle Scholar
  31. Kuhn P, Steiner G (1917) Über die Ursache der multiplen Sklerose. Med Klin 13:1007–1009 Kurtzke J (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5:580–583Google Scholar
  32. Lassman H (1983) Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Springer-Verlag, BerlinGoogle Scholar
  33. Losseff N, Kendall BE, Kingsley DPE, Miller DH, McDonald WI, Thompson AJ (1995) Serial magnetic resonance imaging (MRI) in multiple sclerosis (MS): a five year follow up study. J Neurol 242 (Suppl 2):S7Google Scholar
  34. Ludkin PL, Ellison GW, Ghezzi A (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051–1055CrossRefGoogle Scholar
  35. Marie P (1895) Lectures on diseases of the spinal cord (trans Lubbock M). New Sydenham Society, London 134–136,153Google Scholar
  36. Marinesco G (1919) Etude sur l’origine. nature de la sclerose en plaques. Rev Neurol 35:481–488 Matthews WB (1991) In: Matthews WB McAlpine’s multiple sclerosis, 2nd edn. Churchill Livingstone, Edinburgh pp 251–298Google Scholar
  37. McAlpine D, Compston ND, Lumsden CE (1955) Multiple clerosis. E & S Livingstone, Edinburgh pp 191Google Scholar
  38. McDonald WI (1994) The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol 53:338–343PubMedCrossRefGoogle Scholar
  39. McDonald WI, Miller DH, Thompson AJ (1994) Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilenuna of interferon-beta. Ann Neurol 36:14–18PubMedCrossRefGoogle Scholar
  40. Mohr DC, Neilley L, Gatto N et al. (1995) Expectations of multiple sclerosis patients initiating Betaseron therapy. Neurology 45 (Suppl 4):139PGoogle Scholar
  41. Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: a randomised double-blinded placebo-controlled clinical trial. Ann Neurol 27:591–605CrossRefGoogle Scholar
  42. Nauta JJP, Thompson AJ, Barkhof F, Miller DH (1994) Magnetic resonance imaging in monitoring the treatment in multiple sclerosis patients: statistical power of parallel groups and crossover designs. J Neurol Sci 122:6–14PubMedCrossRefGoogle Scholar
  43. Oppenheim H (1911) Text-book of nervous diseases for physicians and students (trans Bruce A). Otto Schulze, Edinburgh (trans 1908 German edn)Google Scholar
  44. Paty DW, Cousin HK, Read S, Adlakha K (1978) Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit. Acta Neurol Scand 58:53–58PubMedCrossRefGoogle Scholar
  45. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662667Google Scholar
  46. Poser C, Paty D, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRefGoogle Scholar
  47. Purves-Stewart J (1930a) A specific vaccine treatment in disseminated sclerosis. Lancet i:560–564 Purves-Stewart J (1930b) The etiology and treatment of disseminated sclerosis. J Nerv Ment Dis 72:652–660Google Scholar
  48. Putnam TJ (1935) Studies in multiple sclerosis: IV. Encephalitis and sclerotic plaques produced by venular obstruction. Arch Neurol Psychiatry 33:929–940Google Scholar
  49. Putnam TJ, Chiavacci LV, Hoff H et al. (1947) Results of treatment of multiple sclerosis with dicoumarin. Arch Neurol 57:1–13Google Scholar
  50. Rose AS, Cuzma JW, Kurtzke JF et al. (1970) Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo; final report. Neurology 20 (Suppl):1–59PubMedGoogle Scholar
  51. Runmarker B, Andersen 0 (1993) Prognostic factors in multiple sclerosis incidence cohort with 25 years of follow-up. Brain 116:117–134PubMedCrossRefGoogle Scholar
  52. Schumacher GA, Beebe G, Kibler RF et al. (1965) Problems of experimental trials of therapy in multiple sclerosis; report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122:552–568CrossRefGoogle Scholar
  53. Siemerling E (1918) Spirochäten in Gehirn eines Falles von multiplen Sklerose. Berl Kiln Wochenschr 55:273–274Google Scholar
  54. Sinclair HM (1956) Deficiency of the central fatty acids and atherosclerosis, etcetera Lancet 1:381383Google Scholar
  55. Swank RL (1950) Multiple sderosis: a correlation of its incidence with dietary fat. Am J Med Sci 220:441–450CrossRefGoogle Scholar
  56. Swank RL, Lerstead O, Strjaum A, Backer J (1952) Multiple sclerosis in rural Norway: its geo-graphical and occupational incidence in relation to nutrition. N Engl J Med 246:721–728CrossRefGoogle Scholar
  57. Tucker WG, Kapphahn KH (1969) A preliminary evaluation of azathioprine (Irruran) in the treatment of multiple sclerosis. Henry Ford Hosp Med J 17:89–92PubMedGoogle Scholar
  58. Valentiner W (1856) Ueber die Sclerose des Gehirns and Rückenmarks. Deutsche Klinik 8:147–151Google Scholar
  59. Weiner HL, Hauser SL, Hafler DA et al. (1984) The use of cyclophosphamide in the treatment of multiple sclerosis. Ann NY Acad Sci 436:373–381PubMedCrossRefGoogle Scholar
  60. Weinshenker BG, Rice GPA, Noseworthy JH et al. (1991a) The natural history of multiple sclerosis: a geographically based study: 3. Multivariate analysis of predictive factors and models of outcome. Brain 114:1045–1056CrossRefGoogle Scholar
  61. Weinshenker BG, Rice GPA, Noseworthy JH et al. (1991b) The natural history of multiple sclerosis: a geographically based study:4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114:1057–1067CrossRefGoogle Scholar
  62. Whitaker JN, McFarland HF, Rudge P, Reingold SC (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1:37–47PubMedGoogle Scholar
  63. Wiles CM, Omar L, Swan AV et al. (1994) Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 57:154–163PubMedCrossRefGoogle Scholar
  64. Zinsser H (1930) In: Purves Stewart J Discussion. The etiology and treatment of disseminated sclerosis. J Nerv Ment Dis 72:652–660CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1996

Authors and Affiliations

  • W. Ian McDonald

There are no affiliations available

Personalised recommendations